NFL Biosciences climbed 11% on the Paris Bourse on Thursday, after announcing the validation of key stages in the industrialization of its smoking cessation drug candidate, paving the way for production of the first batches in early 2025.

In a press release, the biopharmaceutical company explains that this advance will enable it to increase its manufacturing capacity from a few thousand doses per year to several million units.

In its view, this ramp-up is likely to boost the attractiveness of its NFL-101 to pharmaceutical companies interested in in-licensing, as well as to non-dilutive financing organizations.

The setting up of an industrial organization also suggests the possibility of generating additional future revenues through the sale of manufactured doses to laboratories, the company points out.

Although NFL only has financial visibility until the beginning of the third quarter, analysts at Invest Securities recently estimated that one or more licensing agreements could be announced by the company before its resources run out.

Copyright (c) 2024 CercleFinance.com. All rights reserved.